Recent trends indicate a significant shift in investment focus from AI-driven stocks to Chinese biotech firms, reflecting changing perceptions of market valuations.
In the first quarter of 2025, Chinese companies surged to represent 32% of global biotech licensing deal value, a notable increase from 21% in the previous two years. This shift is largely attributed to Western pharmaceutical companies seeking new pipelines amid patent expirations. Major players like Jiangsu Hengrui and BeiGene have developed substantial drug assets, exemplified by Hengrui's landmark $12.5 billion licensing deal with GSK for rights to HRS-9821. This trend underscores a broader market rotation, as biotech IPOs in the U.S. outperformed AI listings, which have struggled to maintain their earlier momentum.
Investors are increasingly wary of the concentration risk associated with AI-adjacent stocks, primarily comprised of semiconductor and hardware companies. The shift to biotech presents a different risk profile, characterized by tangible revenue streams tied to drug assets rather than speculative infrastructure investments. Chinese biotech firms have adapted their licensing strategies, enabling them to maximize deal value by targeting specific regions separately, showcasing their maturation in the market.
As the landscape evolves, the total licensing deals signed by Chinese biotechs reached $135.7 billion in 2025, with a marked increase in agreements with U.S. and European firms. While the long-term implications of this rotation remain uncertain, it highlights a critical juncture for institutional investors. The current opportunity cost favors Chinese biotech, which is still undervalued compared to Western counterparts. This pivot indicates that while interest in AI remains, the focus is shifting towards companies that can demonstrate actual revenue and robust business models.
Ultimately, this trend suggests a recalibration in investment strategies, where institutional allocators are prioritizing tangible growth narratives over speculative bets in the AI sector. This evolving landscape will likely reshape the competitive dynamics for AI-adjacent startups as they vie for a dwindling pool of institutional capital.